Journal of Clinical Virology 26 (2003) 117 /120 www.elsevier.com/locate/jcv
Erratum
Erratum to ‘‘Antiviral prophylaxis and treatment (excluding HIV therapy)’’ [Journal of Clinical Virology 25 (2002) 241 266] /
S.M.L. Waugh a,*, D. Pillay b, D. Carrington c, W.F. Carman a a
West of Scotland Specialist Virology Centre, Gartnavel General Hospital, Great Western Road, Glasgow G12 OYN, UK b Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK c Public Health Laboratory, Myrtle Road, Kingsdown, Bristol BS2 8EL, UK Accepted 5 August 2002
The publisher regrets that Table 2 in this article was printed incorrectly. The correct Table 2 is shown on the following 3 pages. The fully corrected article is also available free online at http://www.clinical-virology.org
PII of original article: S 1 3 8 6 - 6 5 3 2 ( 0 2 ) 0 0 1 5 1 - 8 * Corresponding author.
1386-6532/03/$ - see front matter # 2003 Elsevier Science B.V. All rights reserved. doi:10.1016/S1386-6532(03)00013-1
Treatment must be started early for optimum effect
Longer courses may be required depending on symptom resolution
Do not use antiviral creams on mucosal surfaces. Herpetic keratitis may require systemic treatment
Avoid in mod-sev renal failure. Reduce dose if mild. Ensure good hydration monitor U&E and creatinine Suspend treatment for 2 recurrences after 6 /12 months
7 days 5 days
Erratum
Uncomplicated
Consider up to 15 mg/kg
Table 2 (Continued ) Indication
Patient group 2 /5 years 6 /12 years Severe disease Adult Child (3 months /12 years) Immunocompromised
Drug
Oral Oral
5 days 5 days
10 mg/kg 8 hourly 250 mg m2 8 hourly
IV IV
5 days 5 days
Longer courses may be required
Aciclovir
Longer courses may be required depending on symptoms 10 mg/kg 8 hourly 15 /18 mg/kg 8 hourly 500 mg/m2 8 hourly
Adult */severe or late presentation Child Zoster (shingles)
Dosea
See above re foscarnet As for foscarnet PLUS: Prehydrate with IV fluids give 2 g oral probenecid 3 h before infusion and 1 g 2 and 8 h after Monitor visual fields and IOP
See notes above
IV Intravitreal Intravitreal
2
119
5 days 5 days
120
Table 2 (Continued ) Indication
Drug
Dosea
Routea
Durationa
Comment/caution
Zanamivir Amantadine
10 mg OD 100 mg OD
Inhaled Oral
6 weeks
3 Oseltamivir has recently been licensed
Ribavirin
3 /7 days
Teratogen (see text)
Palavizumab
20 mg/ml solution over 12 /18 Inhaled (see h per day or 60 mg/ml for 2 h text) BD IM 15 mg/kg 1 /per month
All patients Patients with good response factors
Lamivudine Interferon
100 mg OD 10 million units 3 /per week
Oral SC
12 months/ 4 months
4 4
First choice
Ribavirin (with interferon as bellow)
1 g OD (patient under 75 kg)
SC
6 /12 months
5
Patients where ribavirin is contraindicated
Interferon
1.2 g OD (patient over 75 kg) 3 million units 3/per week
SC SC
6 /12 months 12 months
Patient group
Prophylaxis RSV Treatment
Prophylaxis Hepatitis B virus Chronic disease
All doses from aBNF(43), 2002 and bPrentice et al., 1997; cCouch, 2000; dMalik and Lee, 2000; eBooth et al., 2001.
5 Pegylated interferon is likely to replace interferon